北大医药(000788) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥362,812,695.12, a decrease of 25.50% compared to ¥487,014,401.13 in the same period last year[8] - Net profit attributable to shareholders was ¥10,257,967.08, down 32.19% from ¥15,128,451.92 year-on-year[8] - Basic and diluted earnings per share were both ¥0.0172, representing a decrease of 32.28% from ¥0.0254 in the same period last year[8] - Total operating revenue for Q1 2020 was CNY 362,812,695.12, a decrease from CNY 487,014,401.13 in the previous period[47] - Net profit for Q1 2020 was CNY 10,257,065.86, compared to CNY 15,126,964.87 in the same period last year, representing a decline of approximately 32.5%[49] - The total profit amounted to CNY 14,885,216.23, down from CNY 15,962,971.18, reflecting a decline of 6.7% year-over-year[52] - The total comprehensive income for the period was CNY 12,412,181.49, a decrease from CNY 13,272,973.66 in the same quarter last year[53] Cash Flow - The net cash flow from operating activities was negative at ¥-27,921,120.06, a decline of 124.64% compared to ¥113,334,438.60 in the previous year[8] - Net cash flow from operating activities decreased by 124.64% to -¥27,921,120.06, primarily due to reduced cash collections from business operations[16] - The company incurred a total operating cash outflow of CNY 475,126,976.59, compared to CNY 621,999,207.75 in the same period last year[56] - The company reported a decrease in cash flow from financing activities, with a net cash outflow of CNY -17,888,894.41 compared to a net inflow of CNY 15,137,662.97 in the previous year[57] - The cash flow from investment activities was negative at CNY -10,213,929.21, reflecting an increase in investment expenditures compared to CNY -981,763.19 last year[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,350,760,044.87, down 4.45% from ¥2,460,259,287.17 at the end of the previous year[8] - The company's current assets totaled ¥2,090,925,077.92 as of March 31, 2020, down from ¥2,206,276,422.24 at the end of 2019, indicating a decrease of about 5.2%[39] - The company's total liabilities decreased to ¥1,094,052,280.78 from ¥1,213,922,051.98, marking a decline of approximately 9.8%[41] - Total liabilities at the end of Q1 2020 were CNY 273,256,731.57, down from CNY 314,394,176.46 in the previous period[45] - The company's equity totaled CNY 1,246,337,235.19, with a share capital of CNY 595,987,425.00[64] Shareholder Information - The total number of shareholders at the end of the reporting period was 50,395[11] - The largest shareholder, Southwest Synthetic Pharmaceutical Group Co., Ltd., held 28.58% of the shares, amounting to 170,356,260 shares[11] Research and Development - R&D expenses rose by 118.87% to ¥1,842,713.96, reflecting increased investment in R&D activities[16] - Research and development expenses for Q1 2020 were CNY 1,842,713.96, compared to CNY 841,936.81 in the previous year, indicating an increase of approximately 118%[48] Investment Activities - The company incurred a net cash outflow from investment activities of -¥10,213,929.21, significantly higher than the previous period, due to new product introductions and drug consistency evaluations[16] - The company reported a 940.37% increase in net cash outflow from investment activities, indicating significant investment in new product development[16] - The company signed a technology development contract with Fangzheng Pharmaceutical Research Institute, committing ¥27.5 million for the development of raw materials and tablets[18] - The company has exclusive sales rights for the drug SKL-PSL in China, with a project that has received ethical review approval and completed the first subject screening[17] - The company has a long-term service contract with Peking University International Hospital, estimated at ¥1 billion annually for three years, covering medical supplies and logistics[23] Other Financial Information - The company reported non-recurring gains and losses totaling ¥99,386.08 for the period[9] - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[29] - There were no securities investments or entrusted financial management activities reported during the period[30][31] - The company has not engaged in any derivative investments during the reporting period[32] - The first quarter report was not audited, indicating preliminary financial data[67] - The company adopted new revenue and lease standards starting in 2020, impacting financial reporting[67] - The company has not disclosed any new product developments or market expansion strategies in the current report[67]